To evaluate the effects of acquired resistance to gefitinib/osimertinib on the biological functions in tumor cells, we first measured the IC50 of gefitinib-resistant cells (GR) and osimertinib-resistant cells (OR), and the data showed a significantly increase in IC50 after resistant to EGFR-TKIs inhibitors (Figure 1A and Supplementary Figure 2A). This evidence concerns the gene EGFR and neoplasm.